<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00877357</url>
  </required_header>
  <id_info>
    <org_study_id>SBL/DTPwHBHib/WHOCON/2008/0100</org_study_id>
    <nct_id>NCT00877357</nct_id>
  </id_info>
  <brief_title>Safety, Long Term Immunogenicity and Lot Consistency Study of Liquid Pentavalent Combination Vaccine</brief_title>
  <official_title>Open Label Multicentric Randomized Phase IV Post Marketing Safety, Immunogenicity and Lot-to-Lot Consistency Analysis of Shan 5 [DTPwHB-Hib (Liquid) Pentavalent Combination Vaccine] in Indian Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shantha Biotechnics Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shantha Biotechnics Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized phase IV study of the liquid pentavalent combination vaccine to evaluate the
      safety, immunogenicity (short term and long term) and clinical consistency of three
      production lots of the vaccine.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2009</start_date>
  <completion_date type="Anticipated">February 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Solicited and unsolicited local and systemic adverse events following vaccination</measure>
    <time_frame>4 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seroprotection rates for Diphtheria, Tetanus, Pertussis, Hepatitis B and Hib following 3 doses of the vaccine</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lot Consistency based on safety and Seroprotection rates for Diphtheria, Tetanus, Pertussis, Hepatitis B and Hib following 3 doses of the vaccine from each of the three lots</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Diphtheria</condition>
  <condition>Tetanus</condition>
  <condition>Pertussis</condition>
  <condition>Hepatitis B</condition>
  <condition>Haemophilus Influenzae Type B</condition>
  <arm_group>
    <arm_group_label>Shan 5 Lot No 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Shan 5 Lot No 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Shan 5 Lot No 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Shan 5</intervention_name>
    <description>Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib tetanus toxoid conjugate pentavalent liquid combination vaccine</description>
    <arm_group_label>Shan 5 Lot No 1</arm_group_label>
    <arm_group_label>Shan 5 Lot No 2</arm_group_label>
    <arm_group_label>Shan 5 Lot No 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy children in the age group six to eight weeks

          -  Born after a normal gestational period (36 - 42 weeks)

          -  Mother's HBsAg (hepatitis B surface antigen) assured negative.

          -  Father, mother or legally acceptable representative properly informed about the study
             and having signed the informed consent form.

        Exclusion Criteria:

          -  Administration of immunoglobulin or any blood products since birth.

          -  Use of any investigational, un-registered drug, or vaccine other than the study
             vaccine (with the exception of oral polio vaccination OPV &amp; BCG vaccine) during the
             study period or within 30 days preceding the first dose of the study vaccine.

          -  Previous vaccination or evidence of infection with DTP or Hib.

          -  History of allergic disease or reaction likely to be exacerbated by any component of
             the vaccine including allergy to antibiotics.

          -  Major congenital or hereditary immunodeficiency.

          -  Infants born to mothers known to be HIV positive.

          -  Infants having evidence of disease or fever, history of allergic disease or persistent
             hematological, hepatic, renal, cardiac or respiratory disease and signs of a CNS
             disorder at the time of vaccination.

          -  Infants showing any of the following reactions after any dose of study vaccine will be
             withdrawn for subsequent doses: body temperature more than 40.40C, persistent
             screaming or crying for 3 hours within 48 hours of vaccination, seizures,
             encephalopathy and hypersensitivity reaction.

          -  Parent/s or guardian of subject unable to maintain diary card
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>8 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raman Rao, MD</last_name>
    <role>Study Director</role>
    <affiliation>Shantha Biotechnics Limited</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mandeep S Dhingra, MD</last_name>
    <phone>+91-40-66301000</phone>
    <phone_ext>1801</phone_ext>
    <email>drmandeep@shanthabiotech.co.in</email>
  </overall_contact>
  <location>
    <facility>
      <name>School of Public Health, Post Graduate Institute of Medical Education and Research</name>
      <address>
        <city>Chandigarh</city>
        <state>UT</state>
        <zip>160012</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Madhu Gupta, MD</last_name>
      <phone>+91-172-2755223</phone>
      <email>madhugupta21@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Madhu Gupta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2009</study_first_submitted>
  <study_first_submitted_qc>April 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2009</study_first_posted>
  <last_update_submitted>May 5, 2009</last_update_submitted>
  <last_update_submitted_qc>May 5, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2009</last_update_posted>
  <responsible_party>
    <name_title>VP, Scientific and Medical Affairs</name_title>
    <organization>Shantha Biotechnics Limited</organization>
  </responsible_party>
  <keyword>Vaccine</keyword>
  <keyword>Prevention</keyword>
  <keyword>Diphtheria</keyword>
  <keyword>Tetanus</keyword>
  <keyword>Pertussis</keyword>
  <keyword>Hepatitis B</keyword>
  <keyword>Haemophilus influenzae type b</keyword>
  <keyword>Lot Consistency</keyword>
  <keyword>Long Term Immunogenicity</keyword>
  <keyword>Reactogenicity</keyword>
  <keyword>Healthy infants</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Whooping Cough</mesh_term>
    <mesh_term>Tetanus</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

